Minireviews
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Oct 15, 2022; 14(10): 1903-1917
Published online Oct 15, 2022. doi: 10.4251/wjgo.v14.i10.1903
Neoadjuvant therapy in resectable pancreatic cancer: A promising curative method to improve prognosis
Hao-Qi Zhang, Jing Li, Chun-Lu Tan, Yong-Hua Chen, Zhen-Jiang Zheng, Xu-Bao Liu
Hao-Qi Zhang, Chun-Lu Tan, Yong-Hua Chen, Zhen-Jiang Zheng, Xu-Bao Liu, Department of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Jing Li, Department of Operating Room/West China School of Nursing, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Tan CL and Liu XB designed the study; Zheng ZJ and Chen YH acquired the data; Zhang HQ and Li J analyzed and interpreted the data; Zhang HQ wrote the paper; Tan CL and Liu XB critically revised the manuscript for important intellectual content.
Supported by 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University, No. ZY2017302 1-3-5; Key Research and Development Projects of Sichuan Province, No. 2019YFS0042; Post-Doctor Research Project, West China Hospital, Sichuan University, No. 2020HXBH168; and Key R&D Project of Science and Technology Department of Sichuan Province, No. 2021YFS0107.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chun-Lu Tan, MD, PhD, Associate Professor, Surgeon, Department of Pancreatic Surgery, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Wuhou District, Chengdu 610041, Sichuan Province, China. chunlutan@163.com
Received: June 26, 2022
Peer-review started: June 26, 2022
First decision: July 25, 2022
Revised: August 5, 2022
Accepted: September 8, 2022
Article in press: September 8, 2022
Published online: October 15, 2022
Processing time: 110 Days and 6.3 Hours
Core Tip

Core Tip: In this review, we collate data about risk factors influencing the prognoses of patients with resectable pancreatic cancer from five randomized controlled trials (RCTs) and discuss the possible reasons for the varying outcomes. By comparing the overall survival of two RCTs, we speculated that neoadjuvant therapy might actually benefit patients with low-risk factors for long-term survival. Moreover, we address some suggestions for the RCTs in the future.